Abstract:Background Secondary lymphoid tissue chemokine (SLC) is a key CC chemokine for chemotaxis of immune cells and has been an attractive candidate for anti-tumor treatments. However, among the immune cells recruited by SLC to tumors, the CD25 + Foxp3 + regulatory T cells (Tregs) compromise the anti-tumor effects. In this study, we proposed the combination therapy of intratumoral co-administration of SLC and anti-CD25 monoclonal antibodies (mAbs). We hypothesized that the intratumoral injections of SLC and depletion of Tregs would have stronger inhibition effects on the progression of hepatocellular carcinoma (HCC) in mice. Methods C57BL/6 mice were inoculated subcutaneously with the murine HCC cell line, and mice with visible tumors were treated intratumorally with SLC, SLC plus anti-CD25 mAbs or the control antibodies. The percentages of Tregs, effector CD8 + T cells and CD4 + T cells were checked in the tumors, lymph nodes, spleen and liver at regular intervals. The levels of intratumoral IL-12, IFN-γ, IL-10 and TGF-β1 were evaluated. The final anti-tumor effects were measured by the tumor volume and weight as well as the intratumoral activity of MMP2 and MMP9. Bone-marrow-derived dendritic cells were used to explore the mechanisms of maturation induced by SLC in vitro. Results Our experiments showed the combination therapy significantly decreased the frequency of Tregs, and increased CD8 + T cells and CD4 + T cells at tumor sites. These alterations were accompanied by an increased level of IL-12 and IFN-γ, and decreased level of IL-10 and TGF-β1. Unexpectedly, we observed a significantly decreased percentage of Tregs, and increased CD8 + T cells and CD4 + T cells in the lymph nodes, spleen and liver after the combination therapy. The growth and invasiveness of HCC was also maximally inhibited in the combination therapy compared with the SLC alone. Furthermore, we confirmed SLC induced the maturation of DCs via NF-κB p65 and this maturation would benefit the combination therapy. Conclusions Our data demonstrated that intratumoral co-administration of SLC and anti-CD25 mAbs was an effective treatment for HCC, which was correlated with the altered tumor microenvironment and systemically optimized percentages of Tregs, CD8 + T cells and CD4 + T cells in peripheral immune organs.

Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.

The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector

Recombinant adeno-associated virus encoding secondary lymphoid tissue chemokine(rAAV-SLC) efficiently infected mouse BMDC

More Than Chemotaxis: A New Anti-Tumor DC Vaccine Modified by Raav2-Slc

Soluble Expression of Recombinant Human Secondary Lymphoid Chemokine (SLC) in E. Coli and Research on Its in Vitro and in Vivo Bioactivity.

Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma

Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells

Antitumor Immunity by a Dendritic Cell Vaccine Encoding Secondary Lymphoid Chemokine and Tumor Lysate on Murine Prostate Cancer

Dendritic cells infected with recombinant adenoviral vector encoding mouse fibroblast activation protein-α and human livin α exert an antitumor effect against Lewis lung carcinoma in mice

Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer

Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors.

TO CONSTRUCT A RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR CARRYING THE GENE ENCODING THE MATURE PEPTIDE OF SECONDARY LYMPHOID-TISSUE CHEMOKINE

Tumor Suppressor in Lung Cancer-1 (TSLC1) Mediated by Dual-Regulated Oncolytic Adenovirus Exerts Specific Antitumor Actions in a Mouse Model

Selective in Vivo Targeting of Human Liver Tumors by Optimized Aav3 Vectors in A Murine Xenograft Model

Induction of Specific Immune Response Against Hepatocellular Carcinoma by Human SLC and AFP Vector Transfected Dendritic Cells from CD34+ Hematopoietic Stem Cells

Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.

[388] PEG10 IS OVEREXPRESSED IN HEPATOCELLULAR CARCINOMA AND IS A POTENTIAL TARGET FOR HEPATOCELLULAR CARCINOMA GENE THERAPHY

Efficient delivery of clay-based nanovaccines to the mouse spleen promotes potent anti-tumor immunity for both prevention and treatment of lymphoma

The Spatial and Single-Cell Analysis Reveals Remodeled Immune Microenvironment Induced by Synthetic Oncolytic Adenovirus Treatment.

Recombinant adenovirus of SEA and CD80 genes driven by MMRE and mouse TERT promoter induce effective antitumor immune responses against different types of tumor cells in vitro and in vivo

Cancer Gene Therapy of Adenovirus-Mediated Anti-4-1bb Scfv in Immunocompetent Mice